The US Food and Drug Administration (FDA) has awarded accelerated approval to Karyopharm Therapeutics’ Xpovio (selinexor) to treat relapsed or refractory multiple myeloma (RRMM) in adults.

Xpovio is an oral, selective nuclear export inhibitor of tumour suppressor, growth regulatory and anti-inflammatory proteins. The drug increases anti-cancer activity within the cell.

The FDA’s approval allows the drug to be used in combination with dexamethasone for patients that have received at least four prior therapies and are resistant to certain other treatments.

Accelerated approval is granted to address unmet clinical need based on an endpoint and requires additional trials to confirm a drug’s clinical benefit.

Xpovio’s approval is based on the 25.3% overall response rate (RR) observed in a subgroup of 83 patients in the pivotal Phase IIb STORM trial.

STORM was a multi-centre, single-arm, open-label trial that involved a total of 122 patients that were previously treated with three or more anti-myeloma regimens. Patients received 80mg Xpovio in combination with 20mg dexamethasone on days one and three of each week.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Meanwhile, ongoing, randomised Phase III study BOSTON is set to serve as the confirmatory trial. This study is assessing selinexor plus Velcade (bortezomib) and low-dose dexamethasone.

Karyopharm Therapeutics founder, president and chief scientific officer Sharon Shacham said: “With today’s accelerated approval of XPOVIO by the FDA, patients with heavily pretreated multiple myeloma will now have a new therapeutic option to treat their disease.”

The company expects the new drug to be commercially available in the US on or before 10 July this year. According to Reuters, all four Xpovio dosing packages are priced at $22,000 per month.

The European Medicines Agency (EMA) is currently reviewing a marketing authorisation application for selinexor.